Metformin controlled release - Andrx Corporation

Drug Profile

Metformin controlled release - Andrx Corporation

Alternative Names: ADX 155; Fortamet; Metformin extended-release - Andrx Corporation; Metformin XT

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Andrx Corporation
  • Developer Andrx Corporation; Shionogi Pharma
  • Class Antihyperglycaemics; Biguanides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 19 Apr 2012 First Generic equivalent available in USA for Type-2 diabetes mellitus
  • 08 Dec 2011 First Generic in USA withdrawn pending patent litigation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top